Abacus FCF Advisors LLC Invests $2.70 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Abacus FCF Advisors LLC purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 27,699 shares of the medical equipment provider's stock, valued at approximately $2,703,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC lifted its holdings in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC lifted its stake in Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after buying an additional 435,445 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Lantheus during the 4th quarter worth approximately $36,183,000. Finally, Keybank National Association OH acquired a new stake in shares of Lantheus during the 4th quarter worth about $27,526,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Performance

NASDAQ LNTH traded down $2.31 during trading hours on Friday, hitting $77.83. The company had a trading volume of 1,068,722 shares, compared to its average volume of 1,011,911. The company has a market cap of $5.38 billion, a PE ratio of 12.95 and a beta of 0.11. The business has a 50 day moving average of $88.82 and a 200-day moving average of $91.38. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.69 EPS. Sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insiders Place Their Bets

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director now directly owns 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.